Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Sees Significant Increase in Short Interest
by Tristan Rich · The Markets DailyGenenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 133,286 shares, a growth of 195.0% from the March 15th total of 45,179 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average trading volume of 160,424 shares, the days-to-cover ratio is currently 0.8 days.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of GNTA. Citadel Advisors LLC purchased a new position in Genenta Science in the third quarter valued at about $41,000. Eurizon Capital SGR S.p.A. purchased a new position in Genenta Science in the fourth quarter valued at about $536,000. Norges Bank purchased a new position in Genenta Science in the fourth quarter valued at about $337,000. SmartHarvest Portfolios LLC purchased a new position in Genenta Science in the fourth quarter valued at about $26,000. Finally, Alyeska Investment Group L.P. purchased a new position in Genenta Science in the fourth quarter valued at about $328,000. Hedge funds and other institutional investors own 15.13% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genenta Science currently has a consensus rating of “Sell”.
View Our Latest Report on GNTA
Genenta Science Trading Down 1.5%
Shares of NASDAQ GNTA traded down $0.01 on Friday, hitting $0.67. The company had a trading volume of 31,848 shares, compared to its average volume of 114,828. Genenta Science has a 12-month low of $0.59 and a 12-month high of $10.00. The business has a 50 day moving average of $0.82 and a two-hundred day moving average of $1.69. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.16 and a quick ratio of 14.16.
Genenta Science (NASDAQ:GNTA – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.28. As a group, research analysts predict that Genenta Science will post -0.93 EPS for the current fiscal year.
Genenta Science Company Profile
Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.
Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.